On Saturday, July 4, 2009 12:35 PM, bagher mohammadpour
<bmp1337@yahoo.com> wrote to enquiry@dfid.gov.uk
<enquiry@dfid.gov.uk>;:
B. Mohammad pour,
Paris, France.
bmp1337@yahoo.com
bmp1337@yahoo.com
The Right Honourable Gordon Brown
The Prime minister of England
The Prime minister of England
my previous letter that:
IN IRAN
the struggle between Liberty and Authority
has never been so harsh and bloody
during the last century.
The government uses all his power
against his subjects
no less than against external enemies.
Mill says
“But in political and philosophical theories
success disclose defaults and infirmities
which failure might have concealed from observation.”
So the severity of this struggle
puts a further proof on
the Tyrannical nature of ideological and theological
(as happened in Europe) regimes
the struggle between Liberty and Authority
has never been so harsh and bloody
during the last century.
The government uses all his power
against his subjects
no less than against external enemies.
Mill says
“But in political and philosophical theories
success disclose defaults and infirmities
which failure might have concealed from observation.”
So the severity of this struggle
puts a further proof on
the Tyrannical nature of ideological and theological
(as happened in Europe) regimes
Below you find MHRA belief on the legal status of the crisis in the
pharmaceutical industries of Iran. For some known and unknown reasons, but
predictable and understandable, MHRA has not expressed its detailed opinions
on the subject but they would answer you completely and it will provide the best
proof on all my claims stated in my first letter.
I hope to receive very soon the support of you country in favor of a nation who
are living the darkest period of their history in the last century.
Respectfully yours
B Mohammadpour
RE: An Incredable Report From....a little pharmacist
MHRA Information Centre <info@mhra.gsi.gov.uk>
To:bmp1337@yahoo.com
Dear Mr B Mohammad pour,
Manufacturing sites in the UK and sites in countries that manufacture product for the UK are regularly
inspected to ensure compliance to the EU Good Manufacturing Practice Guidelines (GMP).
If a site fails to meet applicable GMP standard then their license to manufacture pharmaceuticals can
be varied or revoked.
If a site continues to manufacture (ie manufactures without a license and hence illegally) then Enforcement
powers exist such that individuals in the UK can be prosecuted under the Medicines Act.
The penalties applicable in such cases are 2 years imprisonment and/or unlimited fine.
We can not comment on what should or does happens in non EU countries if
Good Manufacturing Practice is not adhered to.
Your sincerely
B J Wright Group Manager Inspection
Medicines and Healthcare products Regulatory AgencyTel: 020 7084 2000
Manufacturing sites in the UK and sites in countries that manufacture product for the UK are regularly
inspected to ensure compliance to the EU Good Manufacturing Practice Guidelines (GMP).
If a site fails to meet applicable GMP standard then their license to manufacture pharmaceuticals can
be varied or revoked.
If a site continues to manufacture (ie manufactures without a license and hence illegally) then Enforcement
powers exist such that individuals in the UK can be prosecuted under the Medicines Act.
The penalties applicable in such cases are 2 years imprisonment and/or unlimited fine.
We can not comment on what should or does happens in non EU countries if
Good Manufacturing Practice is not adhered to.
Your sincerely
B J Wright Group Manager Inspection
Medicines and Healthcare products Regulatory AgencyTel: 020 7084 2000
No comments:
Post a Comment